spacer
home > ebr > winter 2019 > gates and doors
PUBLICATIONS
European Biopharmaceutical Review

Gates and Doors

Important discoveries have enabled continued progress in biopharmaceutical sciences; the Nobel Prize in Chemistry was awarded jointly to Frances Arnold for the directed evolution of enzymes and to George Smith and Sir Gregory Winter for the phage display of peptides and antibodies. This work will accelerate the pace of biopharmaceutical drug discovery and open up opportunities for new agents. The Nobel Prize in physiology or medicine was awarded to James Allison and Tasuku Honjo for the discovery of cancer therapy by the inhibition of negative immune regulation. The result of their research, immune checkpoint therapy, is recognised as the fourth pillar in the fight against cancer, supplementing surgery, radiation, and chemotherapy. It has fundamentally changed the outcome for certain groups of patients with advanced cancers.

At the same time, much work remains to be done in the quest to mitigate chronic diseases. The war on cancer persists as steady progress is made in precision medicine. The majority of recent drug approvals have received breakthrough therapy designation by the FDA. These focus mainly on targeted therapies, reflecting greater understanding of the underlying mechanisms. Among the major tumour types, biomarkers help specify patient treatment protocols and to distinguish different cancers, beyond more than just tissue types.

Cancer immunotherapy studies number in the thousands. The enthusiasm for this approach relates to the stunning success achieved in just a few years – alone or in combination protocols. After initial tissue-specific experience, the field has quickly evolved toward a tissue-agnostic paradigm, based on genetic biomarkers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement